Rituxan Lawsuit News and Information
Rituxan Lawsuit
Side effects of Ritxan may result in the development of a rare, but often-fatal brain infection known as progressive multifocal leukoencephalopathy (PML). At least 57 Rituxan PML brain infection cases have been reported, with a 90% fatality rate.
All Articles Tagged With: "Rituxan"
Additional PML Brain Infection Cases Linked to Tysabri and Rituxan
New cases of a rare brain infection, progressive multifocal leukoencephalopathy (PML), have been liked to the lymphoma and arthritis drug Rituxan and the multiple sclerosis (MS) drug Tysabri. The cases have regulators in the U.S. and Europe searching for ways to reduce the risks of patients developing the often fatal brain infection.
Tysabri Side Effects Linked to 9th PML Infection Case
A new case of a rare, often lethal, brain infection has been linked to the multiple sclerosis drug Tysabri, making it the ninth case of progressive multifocal leukoencephalopathy (PML) infection potentially caused by side effects of Tysabri since the drug was put back on the market in July 2006.
Another Tysabri Brain Infection Reported: 8th PML Infection Since Re-Launch
Biogen Idec Inc. indicates that another multiple sclerosis patient may have developed a rare and potentially life-threatening brain infection known as progresive multifocal leukoencephalopathy from side effects of Tysabri.
Rituxan Fatal Infections Lead FDA to Review Risk of Side Effects
Following reports that link side effects of Rituxan to fatal brain infections, the FDA is reviewing whether users of the cancer-fighting drug should use the medication for shorter periods of time or take “drug holidays” to reduce the risk.
Rituxan PML Brain Infections Reported in 57 People
A new study indicates that at least 57 patients being treated with the lymphoma-fighting drug Rituxan have developed a rare brain infection, known as progressive multifocal leukoencephalitis (PML), and the cases have involved a 90% fatality rate.
Rituxan Side Effects Linked to Progressive Multifocal Leukoencephalopathy (PML)
On Thursday, the FDA notified oncologists, rheumatologists and other healthcare providers that the rheumatoid arthritis drug Rituxan has been linked to a fatal case of progressive multifocal leukoencephalopathy (PML). An update will be made to the prescription information about the risk of developing the rare brain disease.
Contact a Lawyer
Submit information about your potential case to be reviewed by an attorney.
